Is a complete NKTR research report available?

No complete published report is available for Nektar Therapeutics (NKTR) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Nektar Therapeutics (NKTR)

NASDAQ: NKTR · USD

$70.7

-0.09 (-0.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first NKTR analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	2.4B
Revenue (ttm)	55.6M
Net income (ttm)	-158.1M
EPS (ttm)	-$8.09
Shares out	33.8M
Volume	982,912
Beta	1.14
Price target	$153	+116.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 55.6M
Net income (ttm): -158.1M
EPS (ttm): -$8.09
Market cap: 2.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All NKTR indicators

Market & fundamental data

Available fields

227

Groups with data

Currency

USD

Showing 227 of 227 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000906709
Company name	Nektar Therapeutics
Country	United States
Country code	US
Cusip	640268306
Employees	63
Employees Change	2%
Employees Change Percent	3.28
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1994-05-03
Isin	US6402683063
Last refreshed	2026-07-30
Market cap	$2.4B
Market cap category	Mid-Cap
Price	$70.68
Price currency	USD
Rev Per Employee	883,063.49x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2834
Symbol	NKTR
Website	https://www.nektar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.62%
EV Sales Forward	43x
EV/Sales	32.35x
FCF yield	-8.57%
P/B ratio	3.61x
P/S ratio	42.92x
PS Forward	57.05x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-241.98%
EBITDA Margin	-240.63%
Gross margin	100%
Gross Profit	$55.6M
Gross Profit Growth	-14.54%
Gross Profit Growth Q	3.83%
Gross Profit Growth3 Y	-5.27%
Gross Profit Growth5 Y	-11.86%
Net Income	$-158.1M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-284.41%
Profit Margin	-284.18%
Profit Per Employee	$-2.5M
ROA	-15.28
Roa5y	-20.76
ROCE	-19.08
ROE	-53.6
Roe5y	-116.6
ROIC	-173.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-11.56%
Cagr15y	-1.97%
Cagr1y	199.08%
Cagr20y	-6.07%
Cagr3y	105.21%
Cagr5y	-21.94%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	-36.24x
Revenue Growth Q	3.83x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-14.44x
Revenue Growth5 Y	-15.08x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.11
Assets	$763.3M
Cash	$568.6M
Current Assets	$589M
Current Liabilities	$57.7M
Debt	$143.4M
Debt Equity	$0.25
Equity	$576.2M
Interest Coverage	-4.62
Liabilities	$187.1M
Long Term Assets	$174.2M
Long Term Liabilities	$129.3M
Net Cash	$588.2M
Net Cash By Market Cap	$24.63
Net Cash Growth	1,630.3%
Net Debt Equity	$-1.02
Tangible Book Value	$576.2M
Tangible Book Value Per Share	$19.55
WACC	10.82

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.21
Net Working Capital	$-14.7M
Quick ratio	9.92
Working Capital	$531.3M
Working Capital Turnover	$0.16

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-39.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-70.73%
1Y total return	198.86%
200-day SMA	62.88
3Y total return	764.59%
50-day SMA	65.66
50-day SMA vs 200-day SMA	50over200
5Y total return	-71%
All Time High	1,670.4
All Time High Change	-95.77%
All Time High Date	2018-03-12
All Time Low	6.19
All Time Low Change	1,042.03%
All Time Low Date	2023-11-13
ATR	3.77
Beta	1.14
Beta1y	1.25
Beta2y	3.61
Ch YTD	67.17
High	72
High52	109
High52 Date	2026-04-20
High52ch	-35.16%
Low	67.51
Low52	21.02
Low52 Date	2025-08-01
Low52ch	236.25%
Ma50ch	7.65%
Premarket Change Percent	-0.03
Premarket Price	$70.75
Premarket Volume	10,903
Price vs 200-day SMA	12.41%
RSI	55.01
RSI Monthly	59.12
RSI Weekly	54.83
Sharpe ratio	1.58x
Sortino ratio	3.4
Total Return	-39.76%
Tr YTD	67.17
Tr15y	-25.8%
Tr1m	11.05%
Tr1w	1.96%
Tr3m	-15.67%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	8
Analyst Price Target Top	$155
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-2.04
Earnings Revenue Estimate	10,462,016x
Earnings Revenue Estimate Growth	-6.38x
Operating Income	$-124.7M
Operating margin	-224.1
Price target	$153
Price Target Change	$117
Price Target Change Top	$119

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	29,141,808%
Float Percent	86.25%
Net Borrowing	273,969,000
Shares Insiders	0.37%
Shares Institutions	66.16%
Shares Out	33,786,032
Shares Qo Q	21.87%
Shares Yo Y	39.76%
Short Float	23.4%
Short Ratio	5.48
Short Shares	20.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-216.7M
Adjusted OCF	-215,862,000
Average Volume	886,351.8x
Bv Per Share	19.55
CAPEX	$-884,000
Ch10y	-70.73
Ch15y	-25.8
Ch1m	11.05
Ch1w	1.96
Ch1y	198.9
Ch20y	-71.44
Ch3m	-15.67
Ch3y	764.6
Ch5y	-71
Ch6m	96.83
Change	-0.13%
Change From Open	-0.72
Close	70.77
Days Gap	0.59
Depreciation Amortization	751,000
Dollar Volume	69,472,220.2
Earnings Date	2026-08-13
Earnings Time	amc
EBIT	$-134.6M
EBITDA	$-133.9M
EPS	$-8.09
F Score	3
FCF	$-204.6M
FCF EV Yield	-11.37x
FCF Per Share	$-6.06
Financing CF	710,108,000
Fiscal Year End	December
Founded	1,990
Income Tax	$-126,000
Investing CF	-395,675,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2025-06-09
Last Split Type	Reverse
Last10k Filing Date	2026-03-13
Ma150	64.71
Ma150ch	9.22%
Ma20	69.67
Ma20ch	1.44%
Net CF	110,684,000
Next Earnings Date	2026-08-13
Open	71.19
Optionable	Yes
Position In Range	70.6
Post Close	70.68
Postmarket Change Percent	-3.16
Postmarket Price	$68.45
Pre Close	70.77
Price Date	2026-07-29
Ptbv Ratio	4.14
Relative Volume	1.11x
Revenue	55,633,000x
SBC By Revenue	21.76x
Share Based Comp	12,106,000
Tax By Revenue	-0.23x
Tr20y	-71.44%
Tr6m	96.83%
Us State	California
Volume	982,912
Z Score	-3.95

Nektar Therapeutics (NKTR)

Coverage state: Market snapshot only — no published research

Generate the first NKTR analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · NKTR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NKTR indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on NKTR

Frequently asked questions